Synbio Technologies

Call Directions Website Contact the business

Synbio Technologies Empowering scientific discoveries with advanced DNA manufacturing and design solutions.

Synbio Technologies was founded in August of 2013 with the hopes of becoming one of the premier companies within the synthetic biology industry. In order to accomplish this goal, many hurdles were circumvented to continue to move forward and offer our customers the highest quality product possible. By striving to move forward in this industry we have fine-tuned our mechanisms of various synthetic biological applications and continue to do so on a daily basis. This is because we strive to be on the cutting edge of this technology which has led us to make groundbreaking discoveries within this field. In doing so we have developed the world’s first GPS Platform, including genotype, phenotype and synotype. The GPS Platform is what separates us from the rest of the competition within this industry. This platform is broken down into three portions and when combined offers a one stop solution of gene “design-construction-application” process. This streamlined process allows us to offer our customers a unique experience when designing their gene of interest in order to comply with the research interests. In addition to our technologically advanced synthetic biology applications there are hundreds of professionals with experienced track records of success in scientific research and industrial management. We are proud to have such a devoted staff with one goal in mind: to offer our customers with the highest quality product possible within an efficient time-frame. Our staff has perfected and streamlined many of these biological applications in order to comply with our customer’s demands. Please contact us with any questions you may have about our various services that we are currently offering.

🧬 Long Gene Synthesis: Build Beyond the Limits! 🔬Long DNA sequences can be challenging to synthesize due to sequence com...
10/14/2026

🧬 Long Gene Synthesis: Build Beyond the Limits! 🔬

Long DNA sequences can be challenging to synthesize due to sequence complexity, repetitive regions, and assembly accuracy. 🧪 Reliable synthesis strategies help bring ambitious genetic designs to life.

🚀 Need genes over 10 kb? Synbio Technologies offers cost-effective long gene synthesis to support your research.
🔥 Special Offer: 30% OFF Long Gene Synthesis for Sequences >10 kb
💰 More value for your research, at a lower cost!
https://hubs.la/Q04B5zMP0

🧬🤖 Closing the Loop in AI-Driven Drug Discovery with Ainotype!AI drug discovery needs more than predictions—it needs a c...
10/13/2026

🧬🤖 Closing the Loop in AI-Driven Drug Discovery with Ainotype!
AI drug discovery needs more than predictions—it needs a complete DBTL cycle. 🔄

With 13 years of molecular manufacturing expertise, Synbio Technologies’ Ainotype focuses on five essentials:
🔗 Integrated workflows
📋 Clear validation standards
🧪 Complex molecule expertise
⚡ Full-cycle efficiency
🔐 Trusted data governance

🚀 Strategic AIDD partnerships are open! We provide integrated wet-lab validation and data feedback for AI-designed drug candidates. Let’s turn AI designs into experimental insights!
https://hubs.la/Q04zZM_c0

🧬🤖 AIDD: The Power of the Closed LoopAI-driven drug pipelines have grown from 4 in 2017 to 179 in 2026, with 9 reaching ...
10/12/2026

🧬🤖 AIDD: The Power of the Closed Loop
AI-driven drug pipelines have grown from 4 in 2017 to 179 in 2026, with 9 reaching Phase III. 🚀
💰 $8.4B invested in AI drug discovery in 2025 — over 2× the 2023 level.

But more pipelines don't guarantee higher success rates. Designing a molecule computationally is only the beginning; real drug discovery requires synthesis, expression, and experimental validation. 🧪🔬
📊 Data → 🤖 AI Models → 🧪 Experiments → 🔄 New Data → Smarter Models

The real competitive edge? Closing the loop between AI predictions and real-world validation. 💊
https://hubs.ly/Q04zSK9y0

🔬✨Happy National Nanotechnology Day! 🧬🔬Small in scale, big in potential! 🚀From nanoscale drug delivery 💊 to nanobodies 🧪...
10/09/2026

🔬✨Happy National Nanotechnology Day! 🧬🔬
Small in scale, big in potential! 🚀

From nanoscale drug delivery 💊 to nanobodies 🧪, nanotechnology is opening new possibilities in biotechnology, enabling more precise targeting, innovative therapeutics, and next-generation biomedical research. 🧫🧬

🔬 Exploring the nanoscale. Advancing the future of biotech! 🌟
https://hubs.la/Q04zJlnq0

🧬 Recombinant Antibody Expression: From Sequence to Functional ProteinSuccessful antibody expression depends on more tha...
10/08/2026

🧬 Recombinant Antibody Expression: From Sequence to Functional Protein

Successful antibody expression depends on more than the sequence itself. Key factors include:
🧩 Sequence & host optimization — improve expression efficiency
🧫 Expression system — match the platform to the antibody format
⚙️ Purification & QC — ensure yield, purity, and protein integrity

💡 30 mL Recombinant Antibody Expression — Only $239
✅ From gene synthesis to antibody expression & purification
✅ Guaranteed quantity
✅ No charge if the final yield is below 1 mg

🔬 Turn your antibody sequence into a research-ready protein with a streamlined workflow.
https://hubs.la/Q04zz7X00

🧬 Nanobodies: Small Format, Big PotentialWith their compact size and modular architecture, nanobodies (VHHs) are gaining...
10/07/2026

🧬 Nanobodies: Small Format, Big Potential
With their compact size and modular architecture, nanobodies (VHHs) are gaining attention for applications beyond conventional antibody therapeutics. 🔬

💊 Nanobody–Drug Conjugates (NDCs)
Their small molecular format offers opportunities for efficient target engagement and payload delivery, with potential advantages in tissue pe*******on.

🧠 BBB & CNS Delivery
Nanobodies are also being explored as BBB shuttles and brain-targeting modules, addressing one of the major challenges in biologics: limited pe*******on into the central nervous system.

🎯 From target recognition and payload delivery to tissue-specific targeting, nanobody engineering is expanding the design space for next-generation therapeutics.
https://hubs.la/Q04ypvqG0

🧬 What makes a therapeutic antibody development-ready? 🔬✨It’s not just about strong binding. 👇🎯 Specificity🧪 Affinity & ...
10/06/2026

🧬 What makes a therapeutic antibody development-ready? 🔬✨

It’s not just about strong binding. 👇
🎯 Specificity
🧪 Affinity & kinetics
🧬 Humanization
⚙️ Stability & developability
📈 Expression & manufacturability
🔬 Functional activity

From discovery to characterization, every molecular detail matters. 🧩➡️💊
💡 Better design. Better data. Better antibody candidates. 🚀
https://hubs.la/Q04ypvj-0

🧬🤖 From AI Models to AI Agents: The Next Era of Molecular DiscoveryAI is evolving from generating predictions to coordin...
10/05/2026

🧬🤖 From AI Models to AI Agents: The Next Era of Molecular Discovery

AI is evolving from generating predictions to coordinating entire research workflows.
🔬 Identify targets
🧪 Screen & design molecules
🧩 Predict structures & interactions
📊 Evaluate results
🔄 Learn and optimize

The next breakthrough may not come from a single model—but from AI agents that connect models, data, and scientific workflows. 🚀
https://hubs.la/Q04yc71X0

🍂 Q4 Research Rush: Finish Strong with Synbio Technologies 🧬As the year winds down, keep your research moving with smart...
10/02/2026

🍂 Q4 Research Rush: Finish Strong with Synbio Technologies 🧬
As the year winds down, keep your research moving with smart solutions, reliable quality, and competitive savings across our synthetic biology platform—from gene synthesis, and antibody services.

🔥 Q4 Special Offers Are Here
More ways to save. More ways to accelerate your projects. More support for your year-end research goals.
📅 Oct 1 – Dec 31, 2026
⏳ Don’t miss out—Q4 offers are available for a limited time.

Have a project in the pipeline? Let’s make it happen before year-end. 🔬
https://hubs.la/Q04ybVyS0

🧬 CJC-1295 No DAC / Mod GRF(1-29): A Short-Acting GHRH AnalogA closer look at the peptide behind GH-axis research 🔬🧪 29-...
10/01/2026

🧬 CJC-1295 No DAC / Mod GRF(1-29): A Short-Acting GHRH Analog

A closer look at the peptide behind GH-axis research 🔬
🧪 29-aa synthetic GHRH analog
🎯 GHRHR agonist
⏱️ Short-acting profile
📈 Supports research into endogenous pulsatile GH release
🧬 Applications: GH/IGF-1 axis, peptide pharmacology & endocrine research

Unlike the DAC-containing form, Mod GRF(1-29) is characterized as a short-acting GHRH analog, making it an interesting research tool for studying GHRH signaling and GH secretion dynamics. 🔍

High-quality peptide synthesis and analytical characterization help support reproducible, reliable research. 🧪✨
https://hubs.la/Q04ybRNf0

Address

9 Deer Park Drive , Suite J-25
Monmouth Junction, NJ
08852

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Telephone

+17322303003

Alerts

Be the first to know and let us send you an email when Synbio Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Synbio Technologies:

Shortcuts

Share